TELO ▲ +5.3% - Telomir Pharmaceuticals, Inc.
$TELO - Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
Telomir Pharmaceuticals rose 5.3% after announcing the publication of peer-reviewed research demonstrating that its experimental drug Telomir-Zn restored visual function and retinal structure in an age-related macular degeneration model. The positive preclinical data may have encouraged investors about the therapeutic potential of the company's lead candidate for a significant cause of vision loss.
17-SEP-2026 08:30 AM ET
Share this post
More filings for $TELO
TELO ▲ +1.7% - Telomir Pharmaceuticals, Inc.Sep 14, 2026TELO - Telomir Pharmaceuticals, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $TELO filing history →💬 Comments
Loading comments…
Leave a comment
